Compare ALMR & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALMR | ASTH |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Professional Services |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2026 | 2015 |
| Metric | ALMR | ASTH |
|---|---|---|
| Price | $31.89 | $36.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $35.40 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 699.1K | 257.4K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $519,907,752.00 |
| Revenue This Year | $59.79 | $25.15 |
| Revenue Next Year | $39.75 | $10.10 |
| P/E Ratio | ★ N/A | $53.96 |
| Revenue Growth | N/A | ★ 45.90 |
| 52 Week Low | $21.58 | $18.08 |
| 52 Week High | $39.61 | $51.60 |
| Indicator | ALMR | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 47.41 |
| Support Level | $23.52 | $36.55 |
| Resistance Level | $38.64 | $40.05 |
| Average True Range (ATR) | 2.46 | 1.61 |
| MACD | 0.55 | -0.00 |
| Stochastic Oscillator | 100.00 | 27.62 |
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.